BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
about
Systems biology of cisplatin resistance: past, present and futurePrediction of chemo-response in serous ovarian cancerGene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancerCharacterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity.Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.Pathway analysis of genomic data: concepts, methods, and prospects for future development.Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cellsBAD-mediated apoptotic pathway is associated with human cancer developmentPrognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal AdenocarcinomaA novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growthPlasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.BAD overexpression inhibits cell growth and induces apoptosis via mitochondrial-dependent pathway in non-small cell lung cancer.A network-based method for identifying prognostic gene modules in lung squamous carcinoma.TR3 modulates platinum resistance in ovarian cancer.The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.Oncogenes associated with drug resistance in ovarian cancer.Recently identified drug resistance biomarkers in ovarian cancer.Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosisBCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinLinc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.Single-step enrichment by Ti4+-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution.EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
P2860
Q26863585-9C5DE920-CB59-49A0-96C2-38A0544BE0A2Q29248636-BDB4BD0D-0333-439D-A605-CCF5E080587BQ30660745-B111745F-9068-4C15-B635-B00ABFD2C647Q33597112-34C35934-2CE8-4D61-A738-1D37C818B2A6Q33677598-F40F4382-168E-446D-87F6-63F4FA477067Q33823827-0F475247-5124-4551-ABB3-9EB3868738E6Q34223263-A8CF3733-9D93-4780-9EDA-647B47B26AB2Q34486457-FD7FB99D-007B-4C81-80D4-6657D2980DFEQ35167915-12F74B1B-2355-4A77-B5D7-CBE603FF31E7Q35738659-690B0C36-E079-48D5-A8B7-73E4345D7388Q35952832-759480E8-7053-42F7-9036-A3A76B935CD8Q36029643-976DD76F-6BE9-4F95-8102-134D72A768EDQ36072797-BD54FED3-5375-4EFD-8878-4D177FA734B1Q36361670-538AF2A4-B115-4DA7-98CA-ED36E8145078Q36494718-6DCF6FCC-0361-42BA-A06D-FA659802877AQ36640332-B9FEAACA-44CD-4201-A8D9-538D090C3CB6Q36825646-A464B465-478D-413F-996C-1FE92E50D73CQ36908502-C5BD62E6-EF6A-482B-AB70-B18BC5341A3AQ37109663-16D963B1-CC86-46B9-ADC1-0F9FBB2DECCFQ37620325-96F857DE-E953-4538-98D0-7ED3E1D7732CQ37702100-89AEE174-9710-44AF-B692-8234C1A39AD2Q38226577-1E2C4B23-DE44-45D6-9573-491D093373B7Q38741073-A8F96764-88FE-4638-9D7F-E49FA5DCC51CQ38988038-410CAA53-CE0C-454B-BACC-0E6A99002330Q39392319-EF8BB294-994D-4D88-83B8-59D123460F5DQ40056796-06ABE54E-779D-4655-BEB8-1561A6CAEAA4Q42229898-6862E74D-6DF0-44FC-802C-2972A3EB52DAQ52671369-A338EFAE-0ED5-421D-84DA-B3CD1471638BQ54939484-A09244C0-6117-46D2-9970-FD8B429FEA5EQ54984581-0CFEBC6B-A514-46C9-B87F-FD1B26CAE2A1
P2860
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@ast
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@en
type
label
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@ast
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@en
prefLabel
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@ast
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@en
P2093
P2860
P921
P1476
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
@en
P2093
Andrew Berchuck
Ardeshir Hakam
Carolina Moreno
Douglas C Marchion
Dung-Tsa Chen
Elona Bicaku
Gregory C Bloom
Hope M Cottrill
Hye Sook Chon
P2860
P304
P356
10.1158/1078-0432.CCR-11-0735
P407
P577
2011-08-17T00:00:00Z